follow url ImmunoGen Gets Boost on Breast Cancer Drug Survival Results Immunogen (IMGN $14.36) and Roche announced improved overall survival (OS) as well as progression free survival (PFS) in a Phase III trial for its trastuzumab emtansine (T-DM1) drug utilizing Targeted Antibody Payload Technology ( TAP). The trastuzumab (Herceptin) antibody drug conjugate is being developed jointly by […]
buy Lyrica tablets We are in bit of a lull here as the sumer doldrums post earnings has hit many diagnostic stocks. Most stocks in the sector have hit their highs early in July prior to the July AACC Meeting. We will look for drivers for Q4 appreciation, a time of bullish seasonality. Within our focus list here […]
http://universityofhellpress.com/tag/chris-maroulakos/ End of LaNina? The weather is certainly in the news as drought approaches levels not seen since the 30’s. But several reports recently indicate a shift coming in the fall toward an El Nino pattern.I will check in with noted weather forecasters to see if the 2012-13 ski season will be better for the West. […]
Vermillion (VRML) stock outperforming BG Medicine (BGMD) YTD and Past Month Response Genetics thrown into the mix We have dropped the term “Face-Off” due to negative connotations of the “Face-” part. Here is an update since our last post on 7/6/12 post Q2 earnings. We have also added Response Genetics (RGDX $0.91) as it is […]
Regroup and Look for Q4 Drivers A lackluster earnings quarter that evokes the blahs. The hottest Company in the sector Cepheid (CPHD $36.12), took an earnings hit, driving the stock down 30% to the $32 level now recovering. This life science sector has not participated in the recent NASDAQ rally and biopharmaceutical stocks (now looking […]
QQQs Outperforming Biotech ETFs IBB and XBI-Take a Little Off Biotech Stocks are weak again today with both ETFs showing distribution and momentum moving toward the bottom of the channel. Nothing major but 3-5% off July tops. The QQQs continue to outperform today up 0.21%. Large cap biotech losers are Alexion (ALXN $102.6), Biogen-Idec (BIIB […]
Biotechnology Sector Hit with Profit Taking This week’s Barrons: The West Coast Was the Right Coast Wedbush ranked #1 in % change 6 mo (+12.75%), one year (+18.84%) and three year (81.05%) stock picks and Seattle’s McAdams Wright Ragen scored #1 (+14.1%) in % change over 5 years. Wedbush and Rayno Life Sciences are in […]
PO Box 3701
Manhattan Beach CA 90266
(310) 871-1231
rod@rayno.com
Rod Raynovich is the founder of Raygent Associates, a management consulting firm providing business development and strategic marketing services in the life science and medical device area. He publishes his thoughts and analysis on the biotech industry at www.raygent.com.